DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Healing With Venlafaxine After Injury (HELP)

Information source: Rhode Island Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Neck Pain

Intervention: Venlafaxine (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Rhode Island Hospital

Official(s) and/or principal investigator(s):
Samuel A McLean, MD, MPH, Principal Investigator, Affiliation: University of North Carolina, Chapel Hill
Jeffrey Jones, MD, Principal Investigator, Affiliation: Spectrum Health Hospitals
Kirsten Rindal, MD, Principal Investigator, Affiliation: University of Rochester
Gregory Fermann, MD, Principal Investigator, Affiliation: University of Cincinnati

Overall contact:
Samuel A McLean, MD, MPH, Phone: 919-843-5931, Email: smclean@aims.unc.edu

Summary

Purpose: The purpose of this study is to demonstrate the potential efficacy of venlafaxine administration in reducing acute and chronic musculoskeletal pain in individuals presenting to the ED for evaluation after motor vehicle collision. Participants: Participants will consist of 60 patients between the ages of 18-50 who present to the ED within 12 hours post-motor vehicle collision. Patients who report a neck pain score > 6 will be screened for further eligibility. Procedures (methods): Using a placebo-controlled, randomized, double-blind trial design, 60 high risk patients will be randomized to venlafaxine vs. placebo in the ED. The ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed during serial short-term telephone follow-ups as well as more in-depth follow-ups at 6 weeks, 4 months, and 6 months post-MVC.

Clinical Details

Official title: Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Average neck pain

Secondary outcome: Chronic neck pain

Detailed description: Results from both animal and human studies suggest that treatment with the serotonin-norepinephrine reuptake inhibitor (SNRIs) venlafaxine may reduce post-MVC pain. In addition, venlafaxine has been shown to be beneficial in reducing posttraumatic stress disorder (PTSD) symptoms, and in some patients PTSD symptoms may contribute to reinforcing pain persistence after trauma. This phase IIB pilot trial will screen patients presenting to the ED after MVC for the presence of severe axial pain (>4 on a 0-10 numeric rating scale). Sixty of these "high risk" patients will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal axial pain will be assessed. Results will be used to design a large-scale RCT assessing the efficacy of venlafaxine intervention in decreasing acute and persistent musculoskeletal pain in high-risk patients presenting to the ED after minor MVC.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Between the ages of 18 and 59

- Presents to ED within 24 hours of MVC

- ED axial pain score greater than or equal to 4 (0-10 NRS)

- Clinically sober

- Willing to provide a blood sample

- Has a telephone

- Has regular access to Internet and an email address

- Able to speak and read English

- Permanent US citizen or has a green card

- Blood pressure reading(s) in ED that, when considered in the context of patient past

and current history, in the investigator's judgment does not exceed acceptable level Exclusion Criteria:

- Axial pain score greater than 0 in the past month (0-10 NRS)

- Clinically unstable

- Fracture (other than fracture of the phalanges)

- Substantial soft tissue injury

- Hepatic failure (acute or chronic)

- Renal failure (acute or chronic)

- Coronary artery disease, including previous MI, Angina, PCTA, etc.

- History of glaucoma

- Previous congestive heart failure

- History of seizure disorder

- History of mania or psychotic disorder

- History of suicidal ideation

- Prisoner

- History and behavior indicates, in the investigator's judgment, that the participant

would likely be noncompliant with the study

- Any other condition that, in the investigator's judgment, would indicate that the

patient in unsuitable for the study (e. g. might interfere with the study, confound interpretation, or endanger patient)

- Currently taking a monoamine oxidase inhibitor

- Currently taking medication with substantial interaction with venlafaxine, or which

could confound interpretation of study results

- Breastfeeding

- If female, either not postmenopausal (having menses within past year), or, if

childbearing potential, positive pregnancy test prior to randomization and not using a medically acceptable form of contraception

- Exceeds acceptable chronic daily opioid use prior to MVC

- Previously on venlafaxine

- Previous allergic reaction to venlafaxine

- Antidepressant use within 2 weeks of study start (4 week if Prozac)

Locations and Contacts

Samuel A McLean, MD, MPH, Phone: 919-843-5931, Email: smclean@aims.unc.edu

Spectrum Health, Grand Rapids, Michigan 49503, United States; Recruiting
Chad Sutliffe, MEd, MHA, Phone: 616-486-2044, Email: chad.sutliffe@spectrumhealth.org
Jeffrey Jones, MD, Principal Investigator

University of Rochester Medical Center, Rochester, New York 14642, United States; Recruiting
Kian Merchant-Borna, MPH, Phone: 585-275-2909, Email: Kian_Merchant-Borna@URMC.Rochester.edu
Kirsten Rindal, MD, Principal Investigator

University of Cincinnati, Cincinnati, Ohio 45267, United States; Recruiting
Jillian Picard, Phone: 513-558-8983, Email: picardjk@ucmail.uc.edu
Gregory Fermann, MD, Principal Investigator

Additional Information

Starting date: October 2012
Last updated: August 4, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017